Nanobiotix S.A. (NBTX)

5.71 -0.02 (-0.35%) At close: 04:00PM EDT

Nanobiotix S.A.

60 rue de Wattignies
Paris 75012
France
33 1 40 26 04 70
https://www.nanobiotix.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 101

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Laurent Levy Ph.D.	Co-Founder, President of the Executive Board & CEO	676.66k	N/A	1973
Mr. Bart Van Rhijn	CFO & Member of Executive Board	600.27k	N/A	1973
Ms. Anne-Juliette Hermant M.A.	Chief People Officer & Member of Executive Board	330k	N/A	1974
Mr. Earl J. Bergey Ph.d.	Co-Founder	N/A	N/A	1955
Mr. Alain Dostie	Chief Operating Officer	N/A	N/A	N/A
Mr. Craig West CFA	Senior Vice President of Investor Relations	N/A	N/A	N/A
Mr. Brandon Owens	VP of Strategic Marketing & Corporate Communication	N/A	N/A	N/A
Mr. Patrick Tricoli M.B.A., Pharm.D.	Global Head of Business Development	N/A	N/A	N/A
Ms. Margaret Galluzzi	VP & Global Head of Clinical Operations	N/A	N/A	N/A
Mr. Ventzislav Vassilev M.D.	VP & Global Head of Safety Vigilance	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Corporate governance

Nanobiotix S.A.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.